3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Colorectal Neoplasms
233
Carcinoma, Non-Small-Cell Lung
132
Breast Neoplasms
121
Glioblastoma
88
Ovarian Neoplasms
86
Carcinoma, Hepatocellular
69
Rectal Neoplasms
64
Brain Neoplasms
57
Lung Neoplasms
55
Neoplasm Metastasis
54
Neoplasms
52
Colonic Neoplasms
50
Fallopian Tube Neoplasms
43
Glioma
40
Carcinoma, Renal Cell
35
Gliosarcoma
34
Melanoma
26
Adenocarcinoma of Lung
26
Pancreatic Neoplasms
23
Liver Neoplasms
23
Uterine Cervical Neoplasms
21
Stomach Neoplasms
21
Recurrence
21
Triple Negative Breast Neoplasms
18
Kidney Neoplasms
16
Endometrial Neoplasms
16
Esophageal Neoplasms
15
Astrocytoma
14
Carcinoma, Ovarian Epithelial
13
Adenocarcinoma, Bronchiolo-Alveolar
13
Interventions
Ocoxin
2
niraparib
1
anlotinib
1
Thalidomide
1
Sunitinib
1
Spironolactone
1
Paclitaxel
1
Melphalan
1
Leuprolide
1
Filgrastim
1
Etoposide
1
Doxorubicin
1
Dexamethasone
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
CP protocol
1
Bortezomib
1
Bevacizumab
1
Ascorbic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Endocrine System Diseases
×
Bevacizumab
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled